Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06963476 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

rTMS as Add on Treatment for Substance Use Disorders

StatusCompleted
PhaseNot applicable
Started2025-05-12
View on ClinicalTrials.gov ↗

Amendment history

2026-09-30
Trial completed
Final enrollment: 47 participants (planned 80)
Primary completion confirmed: November 2025 (last estimated May 2026)
2025-06-27
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-05→confirmed 2025-05-12
Study sitesdetails revised at 1 of 1 site
2025-05-08
Study Status, Eligibility v1
Eligibility criteria-3 characters
[...] Use of benzodiazepines in the last 48 hours prior to rTMS. BenzodiazapinesBenzodiazepines are used for duingduring alcohol withdrawal management but then are discontinued pri [...]
2025-05-06
Original filing
Yale University
487 trials monitored
See 35 trials at risk
This pilot study is designed to test feasibility and superiority of rTMS types and target locations for the optimal rTMS intervention for individuals seeking treatment for Alcohol Use Disorder (AUD) or Opioid Use Disorder (OUD). The critical questions this study seeks to answer are: which rTMS type applied to l-dlPFC in OUD participants will induce the greatest reduction of opioid use post-treatment? Is inhibitory rTMS applied to medial prefrontal cortex (mPFC) more effective than excitatory rTMS applied to l-dlPFC at reducing alcohol use post treatment in AUD participants?
Trial Details
NCT Number NCT06963476
Lead Sponsor Yale University
Conditions Opioid Use, Alcohol Use Disorder
Enrollment 47 participants
Start Date 2025-05-12
Primary Completion 2025-11-24 (estimated)
Study Completion 2025-11-24 (estimated)
Updated on ClinicalTrials.gov 2026-09-29